Caribou Biosciences Presents Encouraging Clinical Data from
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell...
Source: globenewswire.com
📰 Updated Phase News
Updated Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Updated Phase. Real-time updates on events, politics, business and more.
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to...
Los Angeles United States Lasika Seneviratne Raj Malik Sacituzumab Govitecan European Society For Medical Oncology
Source: marketscreener.com
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) - G1 Therapeutics (NASDAQ:GTHX)
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data
United States Los Angeles Raj Malik Lasika Seneviratne Sacituzumab Govitecan European Society For Medical Oncology
Source: benzinga.com
G1 Therapeutics Announces Upcoming Presentation at the 2024
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting...
United States American Society Of Clinical Oncology Research Triangle Park Exchange Commission Corporate Communications Therapeutics Inc
Source: globenewswire.com
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting
G1 Therapeutics, Inc. announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjugate sacituzumab govitecan on...
United States American Society Of Clinical Oncology Therapeutics Inc Clinical Oncology Presentation Details Trilaciclib Combined
Source: marketscreener.com
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 -- G1 Therapeutics, Inc. , a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib...
United States Therapeutics Inc American Society Of Clinical Oncology Exchange Commission Research Triangle Park Corporate Communications
Source: marketscreener.com
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1…
Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose (RP2D) continues to demonstrate minimal treatment-related adverse events,…
Source: biztoc.com
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to b
– Updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma to be presented in oral session –– First preclinical data for investigational antibody-drug conjugate SGN-35C to be presented –BOTHELL, Wash.--(BUSINESS WIRE)--#ASH23--Seagen Inc. (NASDAQ: SGEN) t...
Source: pharmiweb.com
Enlivex Therapeutics Ltd.: Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
NES-ZIONA, ISRAEL / ACCESSWIRE / April 12, 2023 / This month, Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced a new clinical collaboration agreement with Beigene Ltd to test a new combination treatment
Shachar Shlosberger Beigene Ltd Yale Cancer Center Enlivex Therapeutics Ltd Enlivex Therapeutics Updated Phase
Source: finanznachrichten.de
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
27.03.2023 - - Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers ...
United States Chris Ogden Sean Mccarthy Stephanie Ascher Bristol Myers Squibb Cytomx Therapeutics Inc
Source: wallstreet-online.de